272 related articles for article (PubMed ID: 23762229)
1. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
Lin SY; Wu ET; Lin CH; Shyu MK; Lee CN
PLoS One; 2013; 8(6):e62983. PubMed ID: 23762229
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
[TBL] [Abstract][Full Text] [Related]
3. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
4. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn.
Blanchard-Rohner G; Meier S; Bel M; Combescure C; Othenin-Girard V; Swali RA; Martinez de Tejada B; Siegrist CA
Pediatr Infect Dis J; 2013 Dec; 32(12):1374-80. PubMed ID: 24569309
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
[TBL] [Abstract][Full Text] [Related]
6. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
Tsatsaris V; Capitant C; Schmitz T; Chazallon C; Bulifon S; Riethmuller D; Picone O; Poulain P; Lewin F; Lainé F; Jacqz-Aigrain E; Aboulker JP; Launay O;
Ann Intern Med; 2011 Dec; 155(11):733-41. PubMed ID: 22147712
[TBL] [Abstract][Full Text] [Related]
7. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
8. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
9. Seropositivity of influenza A H1NI in mothers and infants following maternal vaccination with trivalent seasonal influenza vaccine after the 2009 pandemic.
Chao AS; Chang YL; Chao A; Wu TS; Yang LY; Lian R; Huang YC
Taiwan J Obstet Gynecol; 2017 Feb; 56(1):37-40. PubMed ID: 28254223
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P
Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
[TBL] [Abstract][Full Text] [Related]
14. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy.
Nakashima K; Aoshima M; Ohfuji S; Suzuki K; Katsurada M; Katsurada N; Misawa M; Otsuka Y; Kondo K; Hirota Y
Hum Vaccin Immunother; 2017 Mar; 13(3):543-550. PubMed ID: 27820665
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.
Egunsola O; Clement F; Taplin J; Mastikhina L; Li JW; Lorenzetti DL; Dowsett LE; Noseworthy T
JAMA Netw Open; 2021 Feb; 4(2):e2035693. PubMed ID: 33560425
[TBL] [Abstract][Full Text] [Related]
20. Trivalent influenza vaccine-induced antibody response to circulating influenza a (H3N2) viruses in 2010/11 and 2011/12 seasons.
Hiroi S; Morikawa S; Nakata K; Maeda A; Kanno T; Irie S; Ohfuji S; Hirota Y; Kase T
Hum Vaccin Immunother; 2015; 11(2):386-90. PubMed ID: 25692378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
